Advanz Pharma

acquired/legacy branded and specialty pharmaceuticals

Privately held: no public share price · United Kingdom

Assets

(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
5-HT1D receptorSmall molecule
Migraine
Approved
Autophagy/lysosomal acidificationSmall molecule
Systemic Lupus ErythematosusRheumatoid Arthritis
Approved
Voltage-gated sodium channelsSmall molecule
Epilepsy
Preclinical / Unstaged
VEGF-AProtein / enzyme therapeutic
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.